Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2015, Article ID 124192, 6 pages
http://dx.doi.org/10.1155/2015/124192
Review Article

Novel PET/SPECT Probes for Imaging of Tau in Alzheimer’s Disease

Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan

Received 25 June 2014; Revised 10 September 2014; Accepted 30 September 2014

Academic Editor: Mei Tian

Copyright © 2015 Hiroyuki Watanabe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Johnson, R. Brookmeyer, and K. Ziegler-Graham, “Modeling the effect of Alzheimer's disease on mortality,” International Journal of Biostatistics, vol. 3, pp. 186–191, 2007. View at Publisher · View at Google Scholar · View at MathSciNet
  2. D. J. Selkoe, “Preventing alzheimer's disease,” Science, vol. 337, no. 6101, pp. 1488–1492, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. W. E. Klunk, “Biological markers of Alzheimer's disease,” Neurobiology of Aging, vol. 19, no. 2, pp. 145–147, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. D. J. Selkoe, “Alzheimer's disease: genes, proteins, and therapy,” Physiological Reviews, vol. 81, no. 2, pp. 741–766, 2001. View at Google Scholar · View at Scopus
  5. C. A. Mathis, B. J. Lopresti, and W. E. Klunk, “Impact of amyloid imaging on drug development in Alzheimer's disease,” Nuclear Medicine and Biology, vol. 34, no. 7, pp. 809–822, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. C. A. Mathis, Y. Wang, and W. E. Klunk, “Imaging β-amyloid plaques and neurofibrillary tangles in the aging human brain,” Current Pharmaceutical Design, vol. 10, no. 13, pp. 1469–1492, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Nordberg, “PET imaging of amyloid in Alzheimer's disease,” Lancet Neurology, vol. 3, no. 9, pp. 519–527, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. C. C. Rowe, U. Ackerman, W. Browne et al., “Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism,” The Lancet Neurology, vol. 7, no. 2, pp. 129–135, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. W. Zhang, S. Oya, M.-P. Kung, C. Hou, D. L. Maier, and H. F. Kung, “F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Aβ aggregates in the brain,” Nuclear Medicine and Biology, vol. 32, no. 8, pp. 799–809, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. C. M. Clark, J. A. Schneider, B. J. Bedell et al., “Use of florbetapir-PET for imaging β-amyloid pathology,” The Journal of the American Medical Association, vol. 305, no. 3, pp. 275–283, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S. R. Choi, G. Golding, Z. Zhuang et al., “Preclinical properties of 18F-AV-45: a PET agent for Aβ plaques in the brain,” Journal of Nuclear Medicine, vol. 50, no. 11, pp. 1887–1894, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. D. F. Wong, P. B. Rosenberg, Y. Zhou et al., “In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18),” Journal of Nuclear Medicine, vol. 51, no. 6, pp. 913–920, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Koole, D. M. Lewis, C. Buckley et al., “Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging,” Journal of Nuclear Medicine, vol. 50, no. 5, pp. 818–822, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. D. A. Wolk, I. D. Grachev, C. Buckley et al., “Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology,” Archives of Neurology, vol. 68, no. 11, pp. 1398–1403, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Okamura, T. Suemoto, S. Furumoto et al., “Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease,” Journal of Neuroscience, vol. 25, no. 47, pp. 10857–10862, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. M. T. Fodero-Tavoletti, N. Okamura, S. Furumoto et al., “18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease,” Brain, vol. 134, no. 4, pp. 1089–1100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Okamura, S. Furumoto, R. Harada et al., “Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of Tau pathology in Alzheimer disease,” Journal of Nuclear Medicine, vol. 54, no. 8, pp. 1420–1427, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Giannakopoulos, F. R. Herrmann, T. Bussière et al., “Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease,” Neurology, vol. 60, no. 9, pp. 1495–1500, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Gomez-Isla, R. Hollister, H. West et al., “Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease,” Annals of Neurology, vol. 41, no. 1, pp. 17–24, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. E. D. Agdeppa, V. Kepe, J. Liu et al., “Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease,” The Journal of Neuroscience, vol. 21, no. 24, article RC189, 2001. View at Google Scholar · View at Scopus
  21. G. W. Small, V. Kepe, L. M. Ercoli et al., “PET of brain amyloid and tau in mild cognitive impairment,” The New England Journal of Medicine, vol. 355, no. 25, pp. 2652–2663, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Shin, V. Kepe, J. R. Barrio, and G. W. Small, “The merits of FDDNP-PET imaging in Alzheimers Disease,” Journal of Alzheimer's Disease, vol. 26, no. 1, pp. 135–145, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Okamura, S. Furumoto, M. T. Fodero-Tavoletti et al., “Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET,” Brain, vol. 137, no. 6, pp. 1762–1771, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Zhang, J. Arteaga, D. K. Cashion et al., “A highly selective and specific PET tracer for imaging of tau pathologies,” Journal of Alzheimer's Disease, vol. 31, no. 3, pp. 601–612, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. C. F. Xia, J. Arteaga, G. Chen et al., “[18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease,” Alzheimer's and Dementia, vol. 9, no. 6, pp. 666–676, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Matsumura, M. Ono, S. Hayashi et al., “Phenyldiazenyl benzothiazole derivatives as probes for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains,” MedChemComm, vol. 2, no. 7, pp. 596–600, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Matsumura, M. Ono, H. Kimura et al., “18F-labeled phenyldiazenyl benzothiazole for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains,” ACS Medicinal Chemistry Letters, vol. 3, no. 1, pp. 58–62, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Maruyama, H. Shimada, T. Suhara et al., “Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls,” Neuron, vol. 79, no. 6, pp. 1094–1108, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Harada, N. Okamura, S. Furumoto et al., “Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, no. 1, pp. 125–132, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. C. A. Mathis, Y. Wang, D. P. Holt, G.-F. Huang, M. L. Debnath, and W. E. Klunk, “Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents,” Journal of Medicinal Chemistry, vol. 46, no. 13, pp. 2740–2754, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. W. E. Klunk, H. Engler, A. Nordberg et al., “Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B,” Annals of Neurology, vol. 55, no. 3, pp. 306–319, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Kudo, N. Okamura, S. Furumoto et al., “2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients,” Journal of Nuclear Medicine, vol. 48, no. 4, pp. 553–561, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. V. L. Villemagne, S. Furumoto, M. T. Fodero-Tavoletti et al., “In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 5, pp. 816–826, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. D. T. Chien, A. K. Szardenings, S. Bahri et al., “Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808,” Journal of Alzheimer's Disease, vol. 38, no. 1, pp. 171–184, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. D. T. Chien, S. Bahri, A. K. Szardenings et al., “Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807,” Journal of Alzheimer's Disease, vol. 34, no. 2, pp. 457–468, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. N. S. Honson, R. L. Johnson, W. Huang, J. Inglese, C. P. Austin, and J. Kuret, “Differentiating Alzheimer disease-associated aggregates with small molecules,” Neurobiology of Disease, vol. 28, no. 3, pp. 251–260, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. L. E. Rojo, J. Alzate-Morales, I. N. Saavedra, P. Davies, and R. B. MacCioni, “Selective interaction of lansoprazole and Astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 19, no. 2, pp. 573–589, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. P. J. Riss, L. Brichard, V. Ferrari et al., “Radiosynthesis and characterization of astemizole derivatives as lead compounds toward PET imaging of τ-pathology,” MedChemComm, vol. 4, no. 5, pp. 852–855, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. X. Shao, G. M. Carpenter, T. J. Desmond et al., “Evaluation of [11C]N-methyl lansoprazole as a radiopharmaceutical for PET imaging of tau neurofibrillary tangles,” ACS Medicinal Chemistry Letters, vol. 3, no. 11, pp. 936–941, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. M. V. Fawaz, A. F. Brooks, M. E. Rodnick et al., “High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection,” ACS Chemical Neuroscience, vol. 5, no. 8, pp. 718–730, 2014. View at Publisher · View at Google Scholar
  41. M. Ono, S. Hayashi, K. Matsumura et al., “Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains,” ACS Chemical Neuroscience, vol. 2, no. 5, pp. 269–275, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Tago, S. Furumoto, N. Okamura et al., “Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 57, no. 1, pp. 18–24, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Matsumura, M. Ono, M. Yoshimura et al., “Synthesis and biological evaluation of novel styryl benzimidazole derivatives as probes for imaging of neurofibrillary tangles in Alzheimer's disease,” Bioorganic and Medicinal Chemistry, vol. 21, no. 11, pp. 3356–3362, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Watanabe, M. Ono, H. Kimura et al., “Synthesis and biological evaluation of novel oxindole derivatives for imaging neurofibrillary tangles in Alzheimer's disease,” Bioorganic and Medicinal Chemistry Letters, vol. 22, no. 17, pp. 5700–5703, 2012. View at Publisher · View at Google Scholar · View at Scopus